About
Pazopanib is an oral multi-targeted receptor tyrosine kinase inhibitor (TKI) that selectively inhibits the activity of several key kinases involved in tumor growth and angiogenesis. These include vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-α and -β), and c-Kit. By blocking these pathways, pazopanib effectively inhibits tumor angiogenesis, leading to reduced blood supply to the tumor, and directly suppresses tumor cell proliferation and survival. This dual mechanism of action makes it a potent antineoplastic agent. It is particularly effective in treating advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have previously received chemotherapy, offering a targeted approach to cancer therapy by disrupting critical signaling cascades essential for cancer progression.
Uses
- Treatment of advanced renal cell carcinoma (RCC).
- Management of advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.
- Used in patients with metastatic RCC.
- Second-line therapy for STS after anthracycline-based chemotherapy.
Directions For Use
Take orally once daily, without food (at least one hour before or two hours after a meal), as directed by your oncologist.
Benefits
- Targets multiple pathways involved in cancer growth and angiogenesis.
- Effective in treating advanced renal cell carcinoma.
- Provides a treatment option for advanced soft tissue sarcoma.
- Oral administration offers convenience for patients.
- Can extend progression-free survival in eligible patients.
- Offers a targeted therapy approach.
Side Effects
- Diarrhea
- Nausea and vomiting
- Fatigue
- Hypertension
- Hair color changes (depigmentation)
- Hepatotoxicity (elevated liver enzymes)
- Anorexia
- Headache
- Palmar-plantar erythrodysesthesia (PPE)
- Thrombocytopenia
- Proteinuria
- QT prolongation
Safety Measures
- Alcohol - Avoid alcohol due to potential for increased liver toxicity and exacerbation of gastrointestinal side effects.
- Pregnancy - Contraindicated during pregnancy due to significant risk of fetal harm. Effective contraception is essential for women of childbearing potential.
- Breastfeeding - Discontinue breastfeeding during treatment and for at least 2 weeks after the last dose due to potential for serious adverse reactions in the infant.
- Liver - Significant risk of hepatotoxicity; monitor liver function tests (LFTs) closely and adjust dose or interrupt treatment as needed.
- Kidney - Use with caution in patients with severe renal impairment; dose adjustment may be necessary.
- Lung - Monitor for signs of interstitial lung disease/pneumonitis, which can be severe or fatal, especially in patients with pre-existing lung conditions.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!